BetterLife Pharma (BETRF) Gains from Investment Securities (2019 - 2026)
BetterLife Pharma (BETRF) posted quarterly Gains from Investment Securities of $14785.6 for Q2 2026, up 167.2% year-over-year from $5533.6 in Q2 2025, and up 131.12% quarter-over-quarter from -$47505.5 in Q3 2025.
BetterLife Pharma (BETRF) Gains from Investment Securities (2019 - 2026) Analysis & Trends
BetterLife Pharma's Gains from Investment Securities history runs 8 years deep, the most recent figure standing at $14785.6 for Q2 2026.
- In Q2 2026, Gains from Investment Securities rose 167.2% year-over-year to $14785.6; the TTM figure through Apr 2026 stood at -$56769.0 (down 165.85% YoY), while the FY2021 annual figure was -$601789.7, down 161.16% from the prior year.
- Gains from Investment Securities for Q2 2026 stood at $14785.6, up from -$47505.5 in the prior quarter.
- The five-year high for Gains from Investment Securities was $149825.4 in Q4 2022, with the low at -$65628.0 in Q3 2023.
- The 5-year median for Gains from Investment Securities is $21020.0 (2022), against an average of $29018.6.
- The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities jumped 419.89% in 2022, then plunged 489.94% in 2023.
- BetterLife Pharma's Gains from Investment Securities stood at $149825.4 in 2022, then dropped by 22.3% to $116419.3 in 2023, then plunged by 101.76% to -$2045.3 in 2024, then sank by 2222.68% to -$47505.5 in 2025, then surged by 131.12% to $14785.6 in 2026.
- Business Quant data shows BETRF's Gains from Investment Securities at $14785.6 in Q2 2026, -$47505.5 in Q3 2025, and -$22003.8 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 14,785.63 |
| Apr 30, 2026 | 14,785.63 |
| Jul 31, 2025 | -47,505.46 |
| Jul 31, 2025 | -47,505.46 |
| Apr 30, 2025 | -22,003.84 |
| Apr 30, 2025 | -22,003.84 |
| Oct 31, 2024 | -2,045.28 |
| Oct 31, 2024 | -2,045.28 |
| Jul 31, 2024 | 50,200.91 |
| Jul 31, 2024 | 50,200.91 |
| Apr 30, 2024 | 60,059.96 |
| Apr 30, 2024 | 60,059.96 |
| Oct 31, 2023 | 116,419.31 |
| Oct 31, 2023 | 116,419.31 |
| Jul 31, 2023 | -65,628.01 |
| Jul 31, 2023 | -65,628.01 |
| Apr 30, 2023 | 52,074.14 |
| Apr 30, 2023 | 52,074.14 |
| Oct 31, 2022 | 149,825.44 |
| Oct 31, 2022 | 149,825.44 |